Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib plus Abiraterone in HRD mCRPC
NCT06527690Phase 2Withdrawn
- Sponsor
- Latin American Cooperative Oncology Group
- Start
- Apr 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of niraparib, abiraterone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Latin American Cooperative Oncology Group. Planned start Apr 2025; status: withdrawn.
02
Drugs
niraparibabiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06527690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06527690.